ACNE SPOT CORRECTOR 5 %
BENZOYL PEROXIDE : 5 % · DIN 02435063 · DR. LIN SKINCARE
Health Canada status: CANCELLED (UNRETURNED ANNUAL)
What is ACNE SPOT CORRECTOR?
ACNE SPOT CORRECTOR 5 % contains BENZOYL PEROXIDE : 5 %. It is listed in the Health Canada Drug Product Database under DIN 02435063, held by DR. LIN SKINCARE, supplied as LOTION for TOPICAL administration. Health Canada currently lists it as cancelled (unreturned annual), status dated 04-Apr-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02435063 |
|---|---|
| Brand name | ACNE SPOT CORRECTOR |
| Generic / active ingredient | BENZOYL PEROXIDE : 5 % |
| Manufacturer | DR. LIN SKINCARE |
| Strength | 5 % |
| Dosage form | LOTION |
| Route of administration | TOPICAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | D10AE01 BENZOYL PEROXIDE |
| AHFS class | 84:28.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED (UNRETURNED ANNUAL) |
| Status date | 04-Apr-2018 |
What can be used instead?
Other Canadian products sharing ATC code D10AE01 BENZOYL PEROXIDE. 34 of 208 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACNE CLEARING TREATMENT | 2.5 % | LOTION | RODAN & FIELDS BEAUTY, LLC | MARKETED | DIN 02463202 |
| ACNE FOAMING CLEANSER | 4 % | GEL | CERAVE CANADA | MARKETED | DIN 02508745 |
| ACNE FOAMING CLEANSER | 4 % | GEL | CRLS | MARKETED | DIN 02533715 |
| ACNE TREATMENT LOTION | 5 % | LOTION | VIVIER CANADA INCORPORATED | MARKETED | DIN 02336812 |
| ACTIVE ANTI-ACNE TREATMENT KIT | 2.5 % | LOTION ; KIT | FRUIT OF THE EARTH, INC | MARKETED | DIN 02444054 |
| BENZAC W WASH GEL 10% | 10 % | GEL | GALDERMA CANADA INC | MARKETED | DIN 01925199 |
| BENZAGEL 5 GEL | 5 % | GEL | COLUMBIA LABORATORIES CANADA INC | MARKETED | DIN 02162113 |
| BENZAGEL 5 WASH | 5 % | SOLUTION | COLUMBIA LABORATORIES CANADA INC | MARKETED | DIN 02162121 |
| BENZAGEL SPOT-ON ACNE GEL | 2.5 % | GEL | COLUMBIA LABORATORIES CANADA INC | MARKETED | DIN 02361949 |
| BENZOYL PEROXIDE ACNE TREATMENT 5% | 5 % | GEL | CRLS | MARKETED | DIN 02412012 |
Who else supplies BENZOYL PEROXIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BENZOYL PEROXIDE appears in 24 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.